DC-BASED FLT3L CO-EXPRESSING AIDS VACCINE

基于 DC 的 FLT3L 共表达艾滋病疫苗

• 批准号: 8358157
• 负责人: Stephen Braun
• 金额: $ 5.78万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8358157
• 关键词: AIDS Vaccines; Animals; Antigen-Presenting Cells; Attenuated; Autologous; CD34 gene; Cells; Cytokine Gene; DNA; Dendritic Cells; Disease Progression; Epidemic; Funding; Gene Transfer; Grant; HIV; Hematopoietic; Immune response; Lentivirus Vector; Life; Macaca mulatta; Modeling; National Center for Research Resources; Pathogenicity; Primates; Principal Investigator; Proteins; Research; Research Infrastructure; Resources; SIV; Series; Source; Stem cells; Technology; United States National Institutes of Health; Vaccinated; Vaccination; Vaccines; Viral; Viral Antigens; base; cellular transduction; cost; cytokine; macrophage; nonhuman primate; particle; stem; vector

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Even 25 years after the HIV epidemic began, an effective AIDS vaccine is still unavailable. Multiple vaccine strategies (ie, viral-like particles i.v. or DNA-prime/vector boost i.m.) have been developed to generate immune responses, but none have protected from eventual disease progression. The live-attenuated SIV (nef) in non-human primate models has been shown to induce a strong specific immune response against SIV proteins and to protect animals from subsequent SIV challenge; however, viral replication and pathogenicity has been associated with SIV nef. The focus of this project is to amend AIDS vaccine strategies with gene transfer technologies such as using replication defective lentiviral vectors, co-expressing immuno-modulatory cytokine genes, transducing target cells ex vivo. We are developing a new series of SIV-based lentiviral vectors to efficiently transduce CD34+ hematopoietic stem/progenitor cells ex vivo, expand the transduced cells in culture, induce their differentiation to professional antigen presenting cells (like macrophages or dendritic cells), for expression of viral antigens and the cytokine Flt3L. These transduced cells will be used for vaccination of the autologous host. Vaccinated rhesus will be evaluated for immunological parameters and for protection from challenged with SIVmac.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 即使在艾滋病毒开始流行25年后，仍然没有有效的艾滋病疫苗。多种疫苗策略（即，病毒样颗粒i. v.或DNA初免/载体加强i.m.）已经开发出产生免疫反应，但没有一种能防止最终的疾病进展。 SIV减毒活疫苗（nef）在非人灵长类动物模型中已显示诱导针对SIV蛋白的强特异性免疫应答，并保护动物免受随后的SIV攻击;然而，病毒复制和致病性已与SIV相关 nef。 本项目的重点是利用基因转移技术，如使用复制缺陷型慢病毒载体、共表达免疫调节细胞因子基因、体外转导靶细胞等，来改进艾滋病疫苗策略。 我们正在开发一系列新的基于SIV的慢病毒载体，以有效地体外扩增CD 34+造血干/祖细胞，在培养中扩增转导的细胞，诱导其分化为专职抗原呈递细胞（如巨噬细胞或树突状细胞），用于表达病毒抗原和细胞因子Flt 3L。 这些转导的细胞将用于自体宿主的疫苗接种。 将评价接种恒河猴的免疫学参数和对SIVmac攻毒的保护。